But weight loss alone does not capture the full scope of the 12-month transformation
Tirzepatide (Mounjaro) a dual GLP-1/GIP agonist licensed in the UK for type 2 diabetes and, following a positive NICE technology appraisal (TA1026), recommended for weight management in eligible adults within specialist services
18% of US respondents reported taking prescription drugs for weight loss in 2025, up from 10% in 2024 Source: Euromonitors Voice of the Consumer: Health and Nutrition Survey, fielded February 2024 Legacy weight loss brands turn their attention towards GLP-1 consumers Heritage weight loss companies are shifting focus to accommodate the GLP-1 consumer
Third, retatrutide is a peptide
Diabetes Care 36 , 10671073 (2013)
The Umbrella Labs retatrutide program is structured to reduce those risks through specification forward listing fields and stable catalog references that are easy to incorporate into laboratory recordkeeping
